vimarsana.com
Home
Live Updates
Neoadj T-VEC May Improve Survival in Resectable Melanoma : v
Neoadj T-VEC May Improve Survival in Resectable Melanoma : v
Neoadj T-VEC May Improve Survival in Resectable Melanoma
Offering talimogene laherparepvec before surgery compared with surgery alone could improve event-free as well as overall survival in patients with advanced resectable melanoma, a new analysis suggests.
Related Keywords
Zurich ,
Züsz ,
Switzerland ,
Reinhard Dummer ,
Pierre Fabre ,
Amgen ,
Novartis ,
University Hospital Of Zurich ,
Department Of Dermatology ,
Bristol Myers Squibb ,
University Hospital ,
Merck Sharp ,
Melanoma ,
Malignant Melanoma ,
Skin Cancer ,
Alignant Skin Neoplasm ,
Surgery ,
Neoadjuvant ,
Adjuvant Therapy ,
Biologic Therapy ,
Iologics ,